玻璃体腔注射齐夫-阿柏西普治疗新生血管性年龄相关性黄斑变性:52周结果
这项研究评估了玻璃体腔注射齐夫-阿柏西普(1.25 mg)治疗新生血管性年龄相关性黄斑变性的52周安全性和有效性。15例患者接受每月三次注射后按需治疗,14例完成52周随访;平均最佳矫正视力从基线0.95 ± 0.41(20/200)改善至52周0.75 ± 0.51(20/125)logMAR(P = 0.0066),中心视网膜厚度从478.21 ± 153.48 μm降至304.43 ± 98.59 μm(P = 0.0004)。作者认为齐夫-阿柏西普可能安全有效,但需要更多患者和更长随访确认长期结局。
要点
- 14例完成52周随访,平均最佳矫正视力从基线0.95 ± 0.41(20/200)改善至52周0.75 ± 0.51(20/125)logMAR(P = 0.0066)。
- 中心视网膜厚度从基线478.21 ± 153.48 μm降至52周304.43 ± 98.59 μm(P = 0.0004)。
- 用于评估视网膜毒性的全视野视网膜电图参数(视杆反应和振荡电位)在随访期间保持不变;1例患者在第七次玻璃体腔注射后出现眼内炎症。
核心结论
- 结果提示玻璃体腔注射齐夫-阿柏西普可能对治疗新生血管性年龄相关性黄斑变性安全有效。
- 需要更多患者和更长随访来确认玻璃体腔注射齐夫-阿柏西普的长期结局。
研究设计与样本
- 研究评估玻璃体腔注射齐夫-阿柏西普治疗新生血管性年龄相关性黄斑变性的52周安全性和有效性。
- 所有患者接受三次每月玻璃体腔注射0.05 mL齐夫-阿柏西普(1.25 mg),随后采用按需治疗方案。
- 在基线和每月获取最佳矫正视力和谱域光学相干断层扫描。
- 在基线及第4、13、26、52周获取全视野和多焦视网膜电图。
- 对部分全视野视网膜电图参数,计算基线与52周之间的差值,并比较治疗眼与未治疗对侧眼之间的差值。
主要发现
- 平均最佳矫正视力从基线0.95 ± 0.41(20/200)改善至52周0.75 ± 0.51(20/125)logMAR(P = 0.0066)。
- 基线中心视网膜厚度从478.21 ± 153.48 μm降至52周304.43 ± 98.59 μm(P = 0.0004)。
- 用于评估玻璃体腔注射后视网膜毒性的全视野视网膜电图参数(视杆反应和振荡电位)在随访期间保持不变。
- 5°多焦视网膜电图黄斑反应平均N1-P1振幅增加、P1隐含时间缩短(P < 0.05)。
- 1例患者在第七次玻璃体腔注射后出现眼内炎症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多患者和更长随访来确认玻璃体腔注射齐夫-阿柏西普的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the 52-week safety and efficacy of intravitreal ziv-aflibercept in patients with neovascular age-related macular degeneration. METHODS: All patients received three monthly intravitreal injections of 0.05 mL of ziv-aflibercept (1.25 mg) followed by a pro re nata regimen. The best-corrected visual acuity and spectral domain optical coherence tomography were obtained at baseline and monthly. Full-field and multifocal electroretinograms were obtained at baseline and 4, 13, 26, and 52 weeks. For some full-field electroretinography parameters, we calculated the differences between baseline and 52 weeks and then compared those differences between treated and untreated fellow eyes. RESULTS: Fifteen patients were included and 14 completed the 52-week follow-up. The mean best-corrected visual acuity improved from 0.95 ± 0.41 (20/200) at baseline to 0.75 ± 0.51 (20/125) logarithm of the minimum angle of resolution at 52 weeks (P = 0.0066). The baseline central retinal thickness decreased from 478.21 ± 153.48 μm to 304.43 ± 98.59 μm (P = 0.0004) at 52 weeks. Full-field electroretinography parameters used to assess retinal toxicity after intravitreal injections (rod response and oscillatory potentials) remained unchanged during follow-up. The average multifocal electroretinography macular response in 5° showed increased N1-P1 amplitude and decreased P1 implicit time (P < 0.05). One patient presented with intraocular inflammation after the seventh intravitreal procedure. CONCLUSION: The results suggested that intravitreal ziv-aflibercept might be safe and effective for treating neovascular age-related macular degeneration. More patients and a longer follow-up are needed to confirm the long-term outcomes of intravitreal ziv-aflibercept.
引用
- de Oliveira Dias JR, Costa de Andrade G, Kniggendorf VF, et al. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results. Retina. 2019. PMID: 29232334. doi:10.1097/IAE.0000000000002001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。